News | September 02, 2022
NATCO Pharma to sell stake in Nativita and assets of Pharma division
NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord
NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord
According to industry sales data, Yondelis generated annual sales of $49.7 million for the twelve months ending June 2022 in the US market.
He has over 25+ years of experience in the pharmaceutical Industry and has been working with the company for the past 6 years
The company has reported total income of Rs. 918.9 crores during the period ended June 30, 2022.
The product will be launched by NATCO's commercial partner Viatris.
This lawsuit has been filed in the Pennsylvania Federal Court. NATCO and its marketing partner Mylan
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
The company will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic
The approval is for Ibrutinib tablets 560 mg, 420 mg, 280 mg and 140 mg strengths
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)